BCRX - バイオクリスト・ファ―マシュ―ティカルズ （BioCryst Pharmaceuticals Inc.）

When it comes to penny stocks , a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be strong opportunities. How so? If an insider, such as a C-suite executive or board member, is buying additional shares with their own capital, it’s a positive sign that they are bullish on the company’s future prospects. Fortunately for your average investor, insiders at publicly-traded companies are required to disclose their transactions in filings submitted to the US SEC. Plenty of online stock research tools enable you to filter for stocks where there has been a high level of insider buying. In fact, using these tools, I found seven penny stocks with strong insider buying. Let’s dive into each one, and see whether it is wise to follow their lead. ACER Acer Therapeutics $1.98 ADES Advanced Emissions $2.91 APLD Applied Digital $2.68 BLBX BioCryst $8.79 GLG TD Holdings $1.24 GLT Glatfelter $3.75 PRCH Porch Group $2.21 Acer Therapeutics (ACER) Source: John Brueske / Shutterstock Based in Newton, Massachusetts, Acer Therapeutics (NASDAQ: ACER ) is a clinical-stage biotech company focused on the development of treatments for rare and life-threatening diseases.

The following slide deck was published by BioCryst Pharmaceuticals, Inc.

As of Wednesday, BioCryst Pharmaceuticals Inc.’s (NASDAQ:BCRX) stock closed at $8.83, down from $8.85 the previous day. While BioCryst Pharmaceuticals Inc. has underperformed by -0.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCRX fell by -46.84%, with highs and lows ranging from $18.60 to $7.61, […]

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Clear Channel Outdoor Holdings, Inc. (NYSE:CCO) – Overwhelming stocks appeared first on Stocks Equity .

— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0 attacks per month in 20 of 24 months — RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S and APeX-2 clinical trials which evaluated oral, once-daily ORLADEYO (berotralstat)

In the current trading session, BioCryst Pharmaceuticals Inc.’s (BCRX) stock is trading at the price of $12.96, a gain of 2.53% over last night’s close. So, the stock is trading at a price that is -35.17% less than its 52-week high of $19.99 and 70.30% better than its 52-week low of $7.61. Based on the […]

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel. “We continue to make significant

During the recent session, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s traded shares were 0.43 million, with the beta value of the company hitting 1.98. At the last check today, the stock’s price was $12.37, reflecting an intraday gain of 1.23% or $0.15. The 52-week high for the BCRX share is $19.99, that puts it down -61.6 from … Will BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Boom Or Bust From Here? Read More »

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares, rose in value on Wednesday, 11/16/22, with the stock price down by -2.64% to the previous day’s close as strong demand from buyers drove the stock to $12.89. Actively observing the price movement in the last trading, the stock closed the session at $13.24, falling within a range of $12.85 … BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) Stock Price Will Be Bearish Or Bullish In 2022 Read More »

In today’s recent session, 0.47 million shares of the BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) have been traded, and its beta is 2.50. Most recently the company’s share price was $9.42, and it changed around $0.11 or 1.18% from the last close, which brings the market valuation of the company to $1.60B. BCRX at last check was … Why BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Should Not Be Discarded By Investors In 2022 Read More »

The trading price of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) floating lower at last check on Tuesday, May 31, trading at $9.55, -2.15% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it … If You Don’t Bullish On BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Now, You’ll Regret Your Decision Later Read More »

Related Stocks: BCRX , NVAX , AMGN , ALNY , GILD ,

Meet the winners in our 2022 Life Sciences Awards!

This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ): Clinical-stage biotech with truckloads of cash to take its novel immune tolerance platform past the finish line. Bluebird Bio ( BLUE ): Speculative biotech with a colossal growth runway if the FDA gives its gene therapies the green light. Vistagen Therapeutics ( VTGN ): Unique portfolio of therapeutics which target the nervous system in an industry set for tremendous growth ahead. BioNano Genomics Inc ( BNGO ): This meme stock could develop a long-term recurring revenue-generating machine with its genome image editing tool. Verastem ( VSTM ): This startup develops novel cancer treatments with the goal of delivering the best-in-class RAS pathway product. BioCryst Pharmaceuticals ( BCRX ): Biotech with a robust rare disease drug portfolio and strong liquidity. Source: Mongkolchon Akesin / Shutterstock.com Amidst immense market volatility, investors favor value-oriented sectors to minimize risk.